The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback